Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma

The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma

(2016) Abdalla Mohamed et al.   JOURNAL OF PATHOLOGY

A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis

(2015) Toshiro Moroishi et al.   GENES & DEVELOPMENT

YAP is essential for tissue tension to ensure vertebrate 3D body shape

(2015) Sean Porazinski et al.   NATURE

Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth

(2015) Francesca Zanconato et al.   NATURE CELL BIOLOGY

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma

(2015) Katherine K. Slemmons et al.   PLoS One

The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation

(2014) Annie M. Tremblay et al.   CANCER CELL

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

(2014) Diane D. Shao et al.   CELL

Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover

(2014) X. Hong et al.   EMBO JOURNAL

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

(2014) W. Zhang et al.   Science Signaling

Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors

(2014) J. F. Shern et al.   Cancer Discovery

Viral Small T Oncoproteins Transform Cells by Alleviating Hippo-Pathway-Mediated Inhibition of the YAP Proto-oncogene

(2014) Hung Thanh Nguyen et al.   Cell Reports

Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1

(2013) R. Fan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling

(2012) Fa-Xing Yu et al.   CELL

β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis

(2012) Joseph Rosenbluh et al.   CELL

Threonine-120 Phosphorylation Regulated by Phosphoinositide-3-Kinase/Akt and Mammalian Target of Rapamycin Pathway Signaling Limits the Antitumor Activity of Mammalian Sterile 20-Like Kinase 1

(2012) Filiz Kisaayak Collak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells

(2012) R. N. Judson et al.   JOURNAL OF CELL SCIENCE

Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice

(2012) Miki Nishio et al.   JOURNAL OF CLINICAL INVESTIGATION

Structural and Functional Similarity between the Vgll1-TEAD and the YAP-TEAD Complexes

(2012) Ajaybabu V. Pobbati et al.   STRUCTURE

Evidence for an Unanticipated Relationship between Undifferentiated Pleomorphic Sarcoma and Embryonal Rhabdomyosarcoma

(2011) Brian P. Rubin et al.   CANCER CELL

Role of YAP/TAZ in mechanotransduction

(2011) Sirio Dupont et al.   NATURE

Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells

(2011) S. Hettmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version

(2010) B. Zhao et al.   GENES & DEVELOPMENT

YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas

(2010) Zofia Hélias-Rodzewicz et al.   GENES CHROMOSOMES & CANCER

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

(2010) Jordi Barretina et al.   NATURE GENETICS